It really is starting to feel like 1993 all over again.
First, there is Hillary Clinton proposing a pricing oversight board in response to outrage over perceived excessive price increases. And...
Big Pharma’s Unlikely Price Pledge Leader
Listen to this article
Allergan is taking a page from Big Pharma’s strategy two decades ago to fend off efforts at direct price regulation by pledging restraint on price increases. The differences in the pledge – and the image of the pledge maker – are instructive.
Learn what's happening at the US FDA. On the go.
More from Legislation
- • By
With the US BIOSECURE Act waiting for a Senate vote, there are signs it may be prompting some Chinese firms to look at their operations. In the meantime, two legal experts in China suggest a range of coping strategies for companies that may be deemed "of concern."
- • By
As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.
- • By
US lawmakers will undoubtedly continue to work on pharmacy benefit manager reform legislation in 2025, given its bipartisan support. But policies impacting rebates that could lead to higher premiums in Part D may be a tough sell in the midst of the benefit redesign.
- • By
Neither Kamala Harris nor Donald Trump mentioned drug pricing reforms in their presidential convention speeches.
More from Pink Sheet
- • By
It is unclear in a revised staff manual guide whether Commissioner's National Priority Voucher program approval “recommendations” from the drug and biologic center directors will be advisory or decisional, experts told the Pink Sheet.
- • By
Revised recommendation is based on most recent data on circulating strains in US, where KP.3 is now dominant. Novavax sticks with plans targeting the JN.1 ‘parent strain.’
- • By
Pink Sheet reporter and editors discuss the US FDA’s changes to the COVID-19 vaccine indication and its revocation of the vaccine emergency use authorizations, as well as new vaccine coverage and reimbursement questions.
